Search research articles
Contact Us
Filters
Showing results (441-450 of 510) with videos related to
Page
of 51
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2024
Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial
Lena Saltbæk, Pernille E Bidstrup, Randi V Karlsen, et al.
Cancer Discovery
|
November 6, 2023
Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma
Zhuxuan Li, Xueqian Zhuang, Chun-Hao Pan, et al.
Acta Oncologica (Stockholm, Sweden)
|
January 8, 2025
Work ability following breast cancer - the MyHealth randomized controlled trial
Trine A Horsbøl, Lena Saltbæk, Caroline Urhammer, et al.
Molecular Cancer Therapeutics
|
January 7, 2012
An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735
Kenneth E Hook, Scott J Garza, Maruja E Lira, et al.
Genomics
|
February 26, 2013
Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment
Donghui Huang, Dong-Wan Kim, Athanasios Kotsakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 6, 2023
Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients
Cloud P Paweletz, Grace A Heavey, Yanan Kuang, et al.
Cancer Research
|
May 8, 2007
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y Zou, Qiuhua Li, Joseph H Lee, et al.
Cancer Research
|
March 26, 2009
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma
Tanguy Y Seiwert, Ramasamy Jagadeeswaran, Leonardo Faoro, et al.
Molecular Cancer Therapeutics
|
October 11, 2013
Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871)
Adam Pavlicek, Maruja E Lira, Nathan V Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2011
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib
Jochen K Lennerz, Eunice L Kwak, Allison Ackerman, et al.
Page
of 51
Search research articles
Search
Showing results (441-450 of 510) with videos related to
Sort By:
Page
of 51
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2024
Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial
Lena Saltbæk, Pernille E Bidstrup, Randi V Karlsen, et al.
Cancer Discovery
|
November 6, 2023
Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma
Zhuxuan Li, Xueqian Zhuang, Chun-Hao Pan, et al.
Acta Oncologica (Stockholm, Sweden)
|
January 8, 2025
Work ability following breast cancer - the MyHealth randomized controlled trial
Trine A Horsbøl, Lena Saltbæk, Caroline Urhammer, et al.
Molecular Cancer Therapeutics
|
January 7, 2012
An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735
Kenneth E Hook, Scott J Garza, Maruja E Lira, et al.
Genomics
|
February 26, 2013
Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment
Donghui Huang, Dong-Wan Kim, Athanasios Kotsakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 6, 2023
Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients
Cloud P Paweletz, Grace A Heavey, Yanan Kuang, et al.
Cancer Research
|
May 8, 2007
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y Zou, Qiuhua Li, Joseph H Lee, et al.
Cancer Research
|
March 26, 2009
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma
Tanguy Y Seiwert, Ramasamy Jagadeeswaran, Leonardo Faoro, et al.
Molecular Cancer Therapeutics
|
October 11, 2013
Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871)
Adam Pavlicek, Maruja E Lira, Nathan V Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2011
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib
Jochen K Lennerz, Eunice L Kwak, Allison Ackerman, et al.
Page
of 51